Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C 1311

Drug Profile

C 1311

Alternative Names: C-1311; Imidacrine; Imidazoloacridine; NSC 645809; Symadex; Symadex Pathfinder; XLS-002

Latest Information Update: 16 Jun 2008

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Bradford
  • Developer Antisoma
  • Class Aminoacridines; Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Lymphoid leukaemia; Multiple sclerosis; Rheumatoid arthritis; Solid tumours; Ulcerative colitis

Most Recent Events

  • 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
  • 03 Jun 2008 Final adverse events data from a phase I trial in patients with advanced solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 03 Jun 2008 Efficacy data from a phase II trial in advanced breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top